OncorMed Inc., a Gaithersburg company that provides genetic testing services, says it plans a validation study soon on its new test for bladder cancer.
The study will include an as yet undetermined number of people. It will be supervised by Dr. Mark Schoenberg, an assistant professor of urology at Johns Hopkins Hospital, and is expected to last about a year.
The technology was developed by researchers at Johns Hopkins Hospital and licensed by OncorMed.
OncorMed says the new test was shown to be 95 percent accurate in a pilot study of a small group of patients who had suspicious bladder lesions.
The test uses urine samples to detect bladder cancer by analyzing the DNA from cells present in the urine. Genetic alterations indicate bladder cancer.
Currently, patients with suspected bladder cancer must have an invasive procedure called a cystoscopy to accurately determine if cancer is present.
If the test proves to be highly accurate, it could be approved for widespread use. An estimated 50,000 people in the United States are diagnosed with bladder cancer each year.